OncoMatch/Clinical Trials/NCT06784726
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Is NCT06784726 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Odronextamab and Chimeric Antigen Receptor T-Cell Therapy for recurrent diffuse large b-cell lymphoma.
Treatment: Odronextamab · Chimeric Antigen Receptor T-Cell Therapy — This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of improvement (relapsed) or that have not responded to previous treatment (refractory). Odronextamab is a bispecific antibody that can bind to two different antigens at the same time. Odronextamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Bridging therapy has been used to maintain disease control and to increase the chance of successful receipt of CAR-T cell therapy. However, bridging therapy is typically given after leukapheresis, which does not help prevent disease progression between the decision for CAR-T cell therapy and leukapheresis. Giving odronextamab as bridging therapy before leukapheresis may delay disease progression to allow leukapheresis and increase the likelihood of successful CAR-T cell therapy in patients with relapsed or refractory large B-cell lymphomas.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 antibody therapy
Prior treatment with an anti-CD20 antibody therapy
Cannot have received: anti-CD20 x anti-CD3 bispecific therapy
Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy
Cannot have received: allogeneic stem cell transplantation
Allogeneic stem cell transplantation
Cannot have received: CAR-T cell therapy
Any CAR-T cell therapy
Cannot have received: standard anti-neoplastic chemotherapy (non-biologic)
Exception: within 5-times the half-life or within 2 weeks, whichever is shorter, prior to first administration of study drug
Standard anti-neoplastic chemotherapy (non-biologic) within 5-times the half-life or within 2 weeks, whichever is shorter, prior to first administration of study drug
Cannot have received: standard radiotherapy
Exception: within 2 weeks of first administration of study drug
Standard radiotherapy within 2 weeks of first administration of study drug
Cannot have received: rituximab, alemtuzumab, or other investigational or commercial biologic agent (rituximab, alemtuzumab)
Exception: within 2 weeks prior to first administration of study drug
Treatment with rituximab, alemtuzumab, or other investigational or commercial biologic agent within 2 weeks prior to first administration of study drug
Cannot have received: immunosuppressive therapy (other than biologic)
Exception: within 2 weeks of first administration of study drug
Immunosuppressive therapy (other than biologic) within 2 weeks of first administration of study drug
Cannot have received: investigational non-biologic agent
Exception: within 2 weeks of first administration of study drug
Treatment with an investigational non-biologic agent within 2 weeks of first administration of study drug
Lab requirements
Blood counts
Platelet count ≥ 75 x 10^9 /L; Hemoglobin ≥ 9 g/dL; ANC ≥ 1 x 10^9 /L; For patients with bone marrow involvement or splenic sequestration: Platelet count ≥ 25 x 10^9 /L, Hg ≥ 7.0 g/dL, ANC ≥ 0.5 x 10^9 /L
Kidney function
Creatinine clearance ≥ 50 mL/min calculated by Cockcroft-Gault equation
Liver function
Total bilirubin ≤ 1.5 x ULN, except in patients with Gilbert's syndrome; AST and ALT ≤ 2.5 x ULN
Cardiac function
Left ventricular ejection fraction ≥ 50% and without evidence for pericardial effusion
Creatinine clearance ≥ 50 mL/min calculated by Cockcroft-Gault equation; Total bilirubin ≤ 1.5 x ULN, except in patients with Gilbert's syndrome; AST and ALT ≤ 2.5 x ULN; Platelet count ≥ 75 x 10^9 /L; Hemoglobin ≥ 9 g/dL; ANC ≥ 1 x 10^9 /L; For patients with bone marrow involvement or splenic sequestration: Platelet count ≥ 25 x 10^9 /L, Hg ≥ 7.0 g/dL, ANC ≥ 0.5 x 10^9 /L; Left ventricular ejection fraction ≥ 50% and without evidence for pericardial effusion
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutch/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify